<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02346539</url>
  </required_header>
  <id_info>
    <org_study_id>2014P002495-01</org_study_id>
    <secondary_id>5K01DA029645-04</secondary_id>
    <nct_id>NCT02346539</nct_id>
  </id_info>
  <brief_title>Effect of Nicotine on Brain Reward Pathways</brief_title>
  <official_title>Effect of Nicotine on Brain Reward Pathways</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mclean Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will determine whether an acute dose of nicotine, in the form of the&#xD;
      nicotine lozenge, impacts brain and behavioral measures of mood and reward responsiveness in&#xD;
      individuals with major depressive disorder.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Placebo in functional magnetic resonance imaging (fMRI) BOLD Response</measure>
    <time_frame>Participants will be assessed during 2 fMRI scanning sessions, an expected average of 2 weeks.</time_frame>
    <description>Nicotine will enhance the fMRI BOLD response to monetary reinforcers relative to placebo administration</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Nicotine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2mg of nicotine in the form of a nicotine polacrilex lozenge will be administered orally, one time.&#xD;
4mg of nicotine in the form of a nicotine polacrilex lozenge will be administered orally, one time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine polacrilex</intervention_name>
    <description>Single Acute dose</description>
    <arm_group_label>Nicotine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Nicotine lozenge</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for subjects with Major Depressive Disorder:&#xD;
&#xD;
          1. Provide written informed consent;&#xD;
&#xD;
          2. Both genders and all ethnic origins, age between 18 and 45;&#xD;
&#xD;
          3. Meet DSM-IV diagnostic criteria for MDD (diagnosed with the use of the SCID);&#xD;
&#xD;
          4. A baseline HAM-D score of 16 or greater;&#xD;
&#xD;
          5. Absence of pregnancy;&#xD;
&#xD;
          6. Absence of any psychotropic medication for at least 2 weeks:&#xD;
&#xD;
               1. 6 weeks for fluoxetine&#xD;
&#xD;
               2. 6 months for neuroleptics&#xD;
&#xD;
               3. 2 weeks for benzodiazepines&#xD;
&#xD;
               4. 2 weeks for any other antidepressants&#xD;
&#xD;
        Inclusion Criteria for Healthy Controls&#xD;
&#xD;
          1. Absence of medical, neurological, and psychiatric illness (including alcohol and&#xD;
             substance abuse); as assessed by subject history and a structured clinical interview&#xD;
             (SCID);&#xD;
&#xD;
          2. Provide written informed consent;&#xD;
&#xD;
          3. Both genders and all ethnic origins, age between 18 and 45;&#xD;
&#xD;
          4. Absence of any medications for at least 3 weeks;&#xD;
&#xD;
          5. Absence of pregnancy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with suicidal ideation where outpatient treatment is determined unsafe. These&#xD;
             patients will be immediately referred to a licensed psychologist or psychiatrist to&#xD;
             determine the appropriate clinical treatment;&#xD;
&#xD;
          2. Serious or unstable medical illness&#xD;
&#xD;
          3. Lifetime history of seizure disorder;&#xD;
&#xD;
          4. Lifetime history or current diagnosis of any of the following DSM-IV psychiatric&#xD;
             illnesses: organic mental disorder, schizophrenia, schizoaffective disorder,&#xD;
             delusional disorder, psychotic disorders not otherwise specified, bipolar disorder,&#xD;
             ADHD, patients with mood congruent or mood incongruent psychotic features; simple&#xD;
             phobia, social anxiety disorder and generalized anxiety disorders will be allowed only&#xD;
             if secondary to MDD;&#xD;
&#xD;
          5. Patients with a lifetime history of electroconvulsive therapy (ECT);&#xD;
&#xD;
          6. Failure to meet standard MRI safety requirements;&#xD;
&#xD;
          7. May not have used any nicotine product in the past year; must report fewer than 20&#xD;
             lifetime uses of nicotine&#xD;
&#xD;
          8. Must have an expired carbon monoxide level of less than or equal to 10 ppm.&#xD;
&#xD;
          9. Use of anticholinergic drugs in the past week&#xD;
&#xD;
         10. Any past or present history of cardiac problems including known arrhythmias, acute&#xD;
             coronary syndrome, or ischemic heart disease&#xD;
&#xD;
         11. Uncontrolled hypertension&#xD;
&#xD;
         12. History of substance abuse in the past 6 months (other than caffeine), self-reported&#xD;
             use of marijuana in past month, or history of treatment with methadone&#xD;
&#xD;
         13. Heavy caffeine users (consume greater than 500 mg on a regular or daily basis)&#xD;
&#xD;
         14. Subjects that cannot speak English&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Janes, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mclean Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>January 14, 2015</study_first_submitted>
  <study_first_submitted_qc>January 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2015</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mclean Hospital</investigator_affiliation>
    <investigator_full_name>Amy C. Janes</investigator_full_name>
    <investigator_title>Assistant Professor/Neuroscientist</investigator_title>
  </responsible_party>
  <keyword>Nicotine</keyword>
  <keyword>Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

